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Abstract
Background: Epstein-Barr Virus (EBV)-encoded RNAs (EBERs) are non-polyadenylated RNA molecules transcribed
from the EBV genome by RNA polymerase III (pol III). EBERs are the most abundant viral latent gene products,
although the precise mechanisms by which EBV is able to achieve such high levels of EBER expression are not fully
understood. Previously EBV has been demonstrated to induce transcription factors associated with EBER expression,
including pol III transcription factors and ATF-2. We have recently demonstrated that EBV-encoded nuclear antigen-
1 (EBNA1) induces cellular transcription factors, and given these findings, we investigated the role of EBNA1 in
induction of EBER-associated transcription factors.
Results: Our data confirm that in epithelial cells EBNA1 can enhance cellular pol III transcription. Transient
expression of EBNA1 in Ad/AH cells stably expressing the EBERs led to induction of both EBER1 and EBER2 and
conversely, expression of a dominant negative EBNA1 led to reduced EBER expression in EBV-infected Ad/AH cells.
EBNA1 can induce transcription factors used by EBER genes, including TFIIIC, ATF-2 and c-Myc. A variant chromatin
precipitation procedure showed that EBNA1 is associated with the promoters of these genes but not with the
promoters of pol III-transcribed genes, including the EBERs themselves. Using shRNA knock-down, we confirm the
significance of both ATF-2 and c-Myc in EBER expression. Further, functional induction of a c-Myc fusion protein
led to increased EBER expression, providing c-Myc binding sites upstream of EBER1 were intact. In vivo studies
confirm elevated levels of the 102 kD subunit of TFIIIC in the tumour cells of EBV-positive nasopharyngeal
carcinoma biopsies.
Conclusions: Our findings reveal that EBNA1 is able to enhance EBER expression through induction of cellular
transcription factors and add to the repertoire of EBNA1’s transcription-regulatory properties.
Background
In the 46 years since its discovery, the ubiquitous
Epstein-Barr Virus (EBV) has been found to be closely
associated with a wide range of epithelial and lymphoid
malignancies [1]. During all typical forms of latent EBV
infection and B-cell immortalisation, two highly
expressed gene products are the non-polyadenylated
RNAs, Epstein-Barr Virus encoded RNAs 1 and 2
(EBER1 and EBER2). Although no definitive role for the
EBERs in cell transformation or malignant growth has
been elucidated, several studies highlight the EBERs as
making a significant contribution to EBV-associated
malignancies [2-5] probably through direct interactions
with cellular proteins with which they are known to
form complexes. These include PKR [6,7], RIG-I [8], La
[9] and ribosomal protein L22 [10-12]. In addition, the
EBERs can induce a number of cytokines in lymphocytes
[13,14] and insulin-like growth factor 1 in epithelial cells
[15,16]. Induction of these autocrine growth factors
* Correspondence: j.r.arrand@bham.ac.uk
† Contributed equally
1School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT,
UK
Full list of author information is available at the end of the article
Owen et al. Molecular Cancer 2010, 9:241
http://www.molecular-cancer.com/content/9/1/241
© 2010 Owen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.hints at the transforming role the EBERs may play in
EBV pathology. Indeed, stable expression of EBERs in
immortalised nasopharyngeal epithelial cells confers
resistance to apoptotic stress [17].
EBER1 and EBER2 are transcribed from the EBV gen-
ome by RNA polymerase III (pol III) and as such con-
tain elements (intragenic A and B boxes) typical of
those required for pol III transcription [18,19]. Interest-
ingly, both EBER genes also possess upstream transcrip-
tional regulatory regions that are more typical of pol II
promoters; ATF, Sp1 and TATA binding sites [20]. In
addition, c-Myc has been shown to bind in vitro and in
vivo to two E-Boxes upstream of the EBER1 gene and,
in the context of a minimal promoter, the isolated Myc-
binding locus was transcriptionally active in the pre-
sence of c-Myc [21].
Several oncogenic viruses including hepatitis B virus,
human T-cell leukaemia virus type 1, adenovirus, poly-
oma and SV40, stimulate RNA polymerase III-mediated
transcription by the induction of increased levels of pol
III-specific transcription factors [22-26] and a number
of trans-acting factors are known to be important in the
transcriptional control of the EBERs [2,9,27,28].
Recently, EBV has been shown to induce the cellular
transcription factors TFIIIB and TFIIIC (leading to
induction of general pol III-mediated transcription) and
the typical pol II transcription factor ATF-2, that
enhance expression of EBER1 and EBER2 [29].
Following EBV infection of B-lymphocytes, temporally
the EBERs are the last EBV latent gene product to be
expressed [28,30]. The aforementioned observations
make it tempting to propose that another EBV latent
gene product may be involved in the regulation of EBER
expression through the induction of EBER-specific tran-
scription factors. Indeed, evidence of such a phenomenon
is found in our previous study which demonstrated the
ability of EBNA1 to induce both the transcription of the
genes and activity of the proteins of members of the AP-
1 family, including ATF-2 [31]. EBNA1 is also known to
have transcriptional regulatory properties on the viral Cp,
Qp and LMP1 promoters [32-34].
Although the precise mechanisms by which EBERs
may function in oncogenesis are not yet resolved, it is
clear that they are an important component of the EBV
latent gene complement. In this study, we aim to pin-
point the mechanisms by which EBV is able to increase
EBER expression through induction of transcriptional
components. Specifically, we test the hypothesis that
EBNA1 may be the latent gene product involved in the
regulation of both classic pol II and pol III transcription
factors associated with EBER expression. Our results
confirm the hypothesis and define additional EBNA1-
mediated mechanisms of transcriptional regulation.
Results
EBNA1 induces multiple TFIIIC subunits
EBV has previously been shown to induce RNA poly-
merase III activity via TFIIIC expression in both lym-
phoid and epithelial cells [29], although the viral gene
product responsible for this induction remained uniden-
tified. Affymetrix array analysis revealed a 2.6-fold
induction of RNA encoding the 102kd subunit of TFIIIC
(TFIIIC102) in response to EBNA1 [35], indicating that
this EBV latent gene product may be responsible for
inducing TFIIIC expression. To confirm this observa-
tion, immunohistochemical staining for TFIIIC102 was
conducted and revealed a clear induction of TFIIIC102
in cells expressing EBNA1 (Figure 1). However, the Ad/
AH-EBNA1-cl3 cells that were used in these experi-
ments overexpressed EBNA1 [35]. In order to ensure
that the observed effects of EBNA were not due to non-
physiological levels of expression, another Ad/AH cell
line, Ad/AH-EBNA1-cl8, that stably expresses EBNA1 at
levels comparable to those seen in EBV latently infected
cells (Figure 2) was used in all the following experiments
and is referred to as Ad/AH-EBNA1. The EBNA1 deri-
vatives of AGS and Hone-1 cells were previously shown
to express physiological levels of EBNA1 [35].
Figure 1 Induction of TFIIIC102 by EBNA1. Immunohistochemical staining for TFIIIC-102 in (A) Ad/AH-Neo and (B) Ad/AH-EBNA1-cl3 cells.
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TFIIIC subunits, Q-PCR was carried out for all 5 TFIIIC
subunits that have been shown to respond to EBV [29].
In order to compare directly the effect of EBNA1 and
EBV on TFIII induction, Ad/AH-EBV cells were
included in this analysis. Transcripts encoding TFIIIC
subunits were induced in EBNA1-expressing derivatives
of 3 distinct carcinoma cell models, Ad/AH, AGS and
HONE-1 (Figure 3). As observed previously [29], the
pattern of subunit mRNAs induced varied between cell
types, but in each case EBNA1 induced a statistically
significant enhancement of the expression of at least
two TFIIIC subunits. The effect was most pronounced
in Ad/AH and HONE-1 cells. In contrast, there was no
significant increase in mRNAs encoding the TFIIIB sub-
units Bdp1, Brf1 and TBP (Figure 3). In all cases the
effect of EBNA1 in Ad/AH cells essentially mirrored
that of EBV. We conclude that EBNA1 can have a selec-
tive effect on expression of TFIIIC.
To verify that the transcriptional enhancement
resulted in increased protein expression the levels of
TFIIIC subunits expressed in Ad/AH, Ad/AH-EBNA1
and Ad/AH-EBV cells were examined by immunoblot-
ting (Figure 4). The levels of 4 of the 5 subunits were
found to be induced by EBNA1 to levels equivalent to
those seen following EBV infection. For technical rea-
sons we were unable to confirm the expression of
TFIIIC-102. However, in view of the fact that translation
of the other 4 subunits reflects the induction of the
mRNA and that immunohistochemistry (Figure 1)
shows induction of TFIIIC-102 in response to EBNA1,
we conclude that TFIIIC-102 protein is upregulated and,
like EBV, EBNA1 induces the expression of all 5 TFIIIC
subunits in Ad/AH cells.
EBNA1 increases general pol III-mediated transcription
EBV has previously been shown to increase the expres-
sion of several pol III targets [29,36,37]. To determine
whether this could be due to the expression of EBNA1,
RT-PCR for a number of cellular pol III-transcribed
genes was carried out across the panel of EBNA1-
expressing epithelial cells. Expression of EBNA1 in all
cell lines resulted in increases in expression of the cellu-
lar pol III-transcribed genes tRNA
Tyr,7 S LR N Aa n d5 S
rRNA (Figure 5), similar to those seen in EBV-infected
epithelial cells. Therefore, EBNA1 may be responsible,
at least in part, for the increase in expression of endo-
genous pol III products that is induced by EBV.
Although the induction is quantitatively modest, a com-
parable level of tRNA overexpression has been shown to
be capable of proliferative and oncogenic effects in
immortalised mouse embryonic fibroblasts [38].
EBNA1 induces activated ATF-2
In addition to the influence of pol III-specific transcrip-
tion factors, EBER expression is reliant upon factors
more typically associated with pol II transcription, such
as ATF-2 which has been shown to be increased in
EBV-infected cells [29]. ATF-2 was also found to bind
and activate the promoter of the gene encoding
TFIIIC220 [29]. Consistent with our previous study [31],
a robust increase in levels of ATF-2 mRNA was
observed in EBNA1-expressing Ad/AH cells (Figure 6a),
along with an increase in the total, mono- and dual-
phosphorylated forms of the protein (Figure 6b, 6c, 6d).
EBNA1 increases c-Myc expression and activity
c-Myc has a binding site upstream of the EBER genes
[21] and has been shown to be transcriptionally induced
in EBNA1-expressing Ad/AH cells [35]. This upregula-
tion was confirmed by RT-PCR analysis (Figure 6e). To
assess whether the enhanced expression was associated
with an increase in the transcriptional activation capa-
city of c-Myc, Ad/AH-Neo and -EBNA1 cells stably
expressing a functionally inducible c-Myc fusion protein
(c-MycER) were assessed for c-Myc-mediated activation
of a reporter construct following functional induction of
the c-Myc fusion protein with 4-hydroxytamoxifen (4-
OHT) (Figure 6f). At all tamoxifen concentrations,
enhancement of c-Myc function was observed in both
Neo- and EBNA1-expressing cells, with activity being
around 4- to 5-fold higher in EBNA1-expressing cells
compared with their Neo counterparts. This is consis-
tent with there being an increased transcription-enhan-
cing activity of c-Myc in the presence of EBNA1. In
both Ad/AH-Neo and -EBNA1 cells, the increase of c-
Myc activity in response to 4-OHT treatment was titra-
table, with increased 4-OHT concentrations resulting in
Figure 2 EBNA1 is expressed at physiological levels in Ad/AH-
EBNA1-cl8 cells. Immunoblot analysis of EBNA1 expression in the
epithelial cell lines Ad/AH, Ad/AH-EBNA1-cl8, Ad/AH-EBV, the EBV-
positive NPC line C666-1 and the lymphoblastoid cell lines X50-7
and SL (B-cells immortalised with the B95-8 strain of EBV). Note the
larger size of C666-1 EBNA1, presumably due to a larger Gly-Ala
repeat in this strain of EBV. b-actin served as a loading control.
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Page 3 of 16Figure 3 EBNA1 induces TFIIIC genes, but not TFIIIB transcripts in Ad/AH, AGS, and HONE-1 cells. Levels of transcripts were assayed using
RT-qPCR in epithelial cell lines expressing neomycin control plasmids or EBNA1. For comparative purposes, EBV-infected Ad/AH cells are
included. Fold change values are between neo control cells and EBNA1-expressing or EBV-infected cells, as appropriate. All data are means of
three biological replicates analysed in technical triplicate. Error bars represent the standard deviation in fold change between biological
replicates. Asterisks indicate that the fold change between neo control and EBNA1-transfected or EBV-positive cells is statistically significant.* ,P
≤ 0.05; **, P ≤ 0.01.
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activation.
EBNA1 is present at the promoters of induced, EBER-
associated transcription factor genes but not at the
promoters of pol III-transcribed genes
Previously, we have used ChIP assays to show that
EBNA1 is present at the promoters of several AP-1 sub-
units, including ATF-2, that are transcriptionally
induced by EBNA1 in epithelial cells [31]. Here, we use
a variant (HaloChIP) of conventional ChIP to demon-
strate that EBNA1 is present at the promoters of genes
encoding EBER-associated transcription factors that are
induced in EBNA1-expressing cells. Using a transiently-
expressed fusion protein construct (HaloEBNA1), we
were able specifically to pull-down EBNA1 and asso-
ciated DNA in an antibody-independent manner. The
tagged version of EBNA1 is bound covalently by a resin;
a specific interaction that can be prevented by a block-
ing ligand. We first validated the HaloChIP method by
performing a comparison of HaloChIP with conven-
tional ChIP in EBV-infected Ad/AH cells using an anti-
EBNA1 antibody that, in such assays [39] had already
been demonstrated to be competent to enrich the
known EBNA1-binding DS region of EBV DNA and the
cellular c-jun promoter region [31]. The enrichment
obtained using the two methods was very similar (com-
pare the c-jun data in Figure 7A). Using HaloChIP in
A d / A Hc e l l s ,w ew e r ea b l et oc o n f i r mt h a tt h eE B N A 1 -
fusion protein is present at the ATF-2 and c-Myc pro-
moters through observation of a substantial enrichment
of promoter DNA in experimental samples, compared
with control samples (Figure 7A). Furthermore, we
demonstrate that EBNA1 is present at the promoters of
all TFIIIC subunit genes except TFIIIC63. This is con-
sistent with the fact that TFIIIC63 was unique amongst
the TFIIIC subunit genes in not responding to EBNA1
in Ad/AH cells. We also did not observe any enrich-
ment of promoter DNA for TFIIIB genes or indeed cel-
lular pol III-transcribed genes encoding tRNA
Tyr,5 S
RNA and 7SL RNA. The GAPDH promoter, included as
a negative control, was not enriched in experimental
samples compared with controls.
Figure 4 EBNA1 induces TFIIIC proteins in Ad/AH cells.
Immunoblotting for expression of TFIIIC subunits in protein extracts
from Ad/AH cells expressing neomycin control plasmids or EBNA1,
and in Ad/AH cells infected with EBV.
Figure 5 EBNA1 induces cellular pol III genes in Ad/AH, AGS,
and HONE-1 cells. RT-PCR analysis of the levels of cellular polIII-
transcribed genes tRNA
tyr, 5S rRNA and 7SL RNA in epithelial cell
lines expressing neomycin control plasmids or EBNA1. Band
intensities from experiments conducted in biological triplicate were
quantitated using densitometry and the mean fold change
(± standard deviation (SD)) between EBNA1-positive cells and the
corresponding control is indicated under the appropriate band.
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Page 5 of 16Figure 6 E B N A 1i n d u c e sA T F - 2a n dc - M y ci nA d / A Hc e l l s . (a) RT-PCR analysis shows that transcription of ATF-2 is increased in EBNA1-
expressing cells. (b) Western blot analysis of total, mono- (Thr71) and dual-phosphorylated (Thr69/71) ATF-2 levels in Ad/AH-Neo and -EBNA1
cells. (c) and (d) IF staining for total ATF-2. (e) RT-PCR analysis shows that transcription of c-myc is increased in EBNA1-expressing cells. (f)
Luciferase reporter assay following transient transfection of Ad/AH cells stably expressing c-MycER and either EBNA1 or an empty vector control
plasmid (Neo) with a c-Myc luciferase reporter plasmid (pX-CMVp-Luc) with treatment of cells with 0 nM, 250 nM, 500 nM or 1000 nM 4-
Hydroxytamoxifen for 24 hours.
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ters of cellular pol III-transcribed genes it was of inter-
est to determine whether the enhancement of EBER
expression in EBNA1-expressing cells could be attribu-
ted to EBNA1 binding to the viral EBER promoters.
Since, in the EBV genome, the EBER genes are located
in close proximity to the EBNA1-binding OriP region
[40], this study had to be performed in the Ad/AH-
EBERs cell line, (see Methods) in which the EBERs are
stably expressed from their native promoter elements in
the absence of OriP which would have hampered the
interpretation of ChIP assay data. HaloChIP assays per-
formed in this cell line revealed a level of enrichment of
the ATF2 promoter similar to that observed in Ad/AH-
EBV cells. In contrast, as with the cellular pol III-tran-
scribed genes, there was no enrichment of promoter
DNA for the EBERs (Figure 7A, 7B).
Transient expression of EBNA1 increases levels of EBER
expression
The data presented above confirm that EBNA1 is able
to induce several factors involved in the regulation of
EBER expression (TFIIIC, ATF-2 and c-Myc). However,
these experiments fail to illustrate definitively that
EBNA1 increases EBER expression. To address this, an
EBNA1-expressing plasmid (pSG5 EBNA1) was titrated
into the Ad/AH-EBERs cell line and the effect on EBER
expression was assessed by RT-PCR (Figure 8a). Small
amounts (down to 1ng) of EBNA1-encoding plasmid
DNA were sufficient to increase levels of expression of
both EBER1 and EBER2. This increase can be attributed
to changes in shared components of the pol III machin-
ery, since levels of tRNA transcripts are also increased.
It is noteworthy that even the lowest level of EBNA1 is
sufficient to elicit the responses and that overexpression
is not required. Levels of EBER expression are shown to
be comparable to those seen in the Burkitt’s Lymphoma
(BL) cell line Namalwa (Figure 8b).
A dominant negative EBNA1 (dnEBNA1) reduces EBER
expression in EBV-infected Ad/AH cells
As a converse of the experiments described above, abla-
tion of EBNA1 function through introduction and
expression of dnEBNA1 (EBNA1 M1) in EBV-infected
Ad/AH cells resulted in a robust decrease in levels of
both EBER 1 and EBER 2 expression (Figure 8c).
Figure 7 EBNA1 is present at the promoters of induced, EBER-associated transcription factor genes but not at the promoters of pol III
transcribed genes. PCR for target promoter region DNA was performed for multiple genes on cross-linked genomic DNA pulled down by
HaloEBNA1 fusion protein or, as control, when pull down of HaloEBNA1 and associated cross-linked DNA was specifically blocked by a blocking
ligand. Following gel elecrophoresis of PCR products, band intensities were quantitated using densitometry. Experiments were conducted in
biological triplicate and the mean enrichment between target and control is indicated by the grey bars. A) The black bars at the left of the
figure are the enrichments obtained using conventional ChIP in EBV-infected Ad/AH cells using an anti-EBNA1 antibody versus isotype control
for the known EBNA1-binding dyad symmetry region within ori-P of EBV (EBV-DS) and for the c-jun promoter region (c-jun). Primer sets for
promoter regions were within 1Kb upstream of the transcriptional start site. 5S RNA, tRNA
Tyr and 7SL RNA refer to intragenic promoter regions
for these pol III-transcribed genes whilst 7SL UR refers to the upstream regulatory region of 7SL RNA. B) Enrichments for ATF2 and EBER
promoter regions obtained using HaloEBNA1 pull-down in Ad/AH-EBERs cells.
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Tyr and EBER expression in response to
transient expression of increasing amounts of EBNA1 in the EBER-expressing cell line Ad/AH-EBERs. The experiments were conducted in
biological triplicate. Numbers below the bands in the EBER1, EBER2 and tRNA rows represent the mean fold increase (± SD) in expression
between the EBNA1-positive cells and the control as assessed by densitometry. (b) RT-PCR comparing EBER and EBNA1 expression in AdAH cell
lines with levels seen in the Burkitt’s lymphoma-derived cell line, Namalwa. (c) EBER expression in Ad/AH-rEBV cells transiently transfected with
dominant negative EBNA1 vector or pSG5 control plasmid. Numbers to the right indicate the mean fold decrease (± SD) of EBER expression in
triplicate experiments.
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influenced by EBNA1 reduces EBER expression
To confirm the influence of EBNA1-induced transcrip-
tion factors ATF-2 and c-Myc on EBER expression, we
used shRNA-mediated knock-down of these factors in
EBV-infected Ad/AH cells and examined, using RT-
PCR, the effect on EBER expression. shRNA targeting
ATF-2 robustly reduced ATF-2 expression and, as a
result, expression of both EBER1 and EBER2 was signifi-
cantly diminished (Figure 9a).
shRNA targeting c-Myc also successfully reduced
levels of c-Myc transcription in EBV-infected Ad/AH
cells, and was associated with a diminished level of
EBER1 but no apparent reduction in that of EBER2 (Fig-
ure 9b). This is consistent with the observation that only
the EBER1 gene contains an E-Box (c-Myc binding site)
Figure 9 ATF-2 and c-Myc induction is significant in regulating EBER expression. RT-PCR was used to assay (a) EBER expression following
transient shRNA knock-down of ATF-2; (b) EBER expression following transient shRNA knock-down of c-Myc; (c) EBER expression following
tamoxifen induction of c-MycER in Ad/AH-EBERs cells; (d) EBER expression following tamoxifen induction of c-MycER in Ad/AH ΔX EBER cells with
the c-Myc binding site (X-box upstream of EBER1) excised. Numbers to the right of the gel images indicate the mean fold change (± SD) of
expression in triplicate experiments.
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Page 9 of 16upstream of its transcriptional start site [21]. Previously,
c-Myc has been shown to increase levels of pol III tran-
scription directly by interacting with TFIIIB subunits
[41]. Consistent with this, RT-PCR conducted for endo-
genous pol III targets (Figure 9b) showed that shRNA-
mediated depletion of c-Myc reduced expression of cel-
lular pol III products (data shown for tRNA
Tyr).
Induction of a functional c-Myc influences EBER
expression
To assess further the contribution of EBNA1’s ability to
enhance the transcriptional activation potential of c-
Myc leading to increased EBER expression, an Ad/AH
cell line was generated which stably expressed both c-
MycER and the EBERs (including their upstream tran-
scriptional regulatory regions). Following functional
induction of c-Myc, levels of EBER expression were
assessed (Figure 9c). After 24 hours of induction, a clear
increase in the level of EBER1 was observed, but only a
very modest increase in that of EBER2. This result is
consistent with the shRNA data and supports the idea
of the E-boxes upstream of EBER1 being important in
terms of transcriptional regulation of the EBERs. To
confirm this, an Ad/AH cell line was generated which
stably carried both c-MycER and the EBERs, including
their upstream transcriptional regulatory regions
(TATA, SP1 and ATF sites), but with a ~230 bp region
containing the E-boxes excised (see Materials and Meth-
ods). Again, levels of EBER expression were assessed by
RT-PCR following induction (Figure 9d). Levels of
EBER1 or EBER2 expression were not significantly
increased upon functional induction of c-Myc in this
cell line, again indicating that c-Myc influences EBER
transcription via the upstream E-boxes.
TFIIIC102 is upregulated in EBV-positive NPC tumour cells
The potential relevance in vivo of our observations of
EBNA1-induced induction of TFIIIC102 was addressed
by immunohistochemical staining of EBV-positive NPC
tumour biopsies (Figure 10a - d). In 18 out of 19 NPC
biopsies, nuclear staining for TFIIIC102 appeared signif-
icantly stronger in tumour cells than in infiltrating non-
tumour cells. Additionally, microarray analysis of RNA
extracted from 15 samples of microdissected EBV-posi-
tive NPC tumour cells compared with 4 samples from
normal epithelial cells, revealed consistent induction of
TFIIIC102 mRNA in the tumours (Figure 10e). Expres-
sion of other TFIIIC subunits was variable and so low in
many samples as to be called “absent” by the analysis
software.
Discussion
It has long been established that high levels of EBER
expression are a feature of cells latently infected with
EBV and in cells of EBV-associated malignancies [18].
The findings presented here provide evidence that
EBNA1 plays a significant role in the regulation of
EBER expression in epithelial cells. We show that
EBNA1, like the adenovirus E1A protein [24] and the T-
antigens of polyomaviruses [22,25], increases cellular pol
III transcription and induces expression of specific
TFIIIC subunits. In addition, other EBER-associated
Figure 10 TFIIIC-102 is upregulated in EBV-positive NPC tumour cells. Serial sections of an NPC biopsy were (A) stained with haematoxylin
and eosin; (B) shown to contain strongly EBER-positive tumour cells by in situ hybridisation; (C) strongly positive for TFIIIC-102 compared with
the surrounding stromal, non-tumour cells. (D) Shows similar staining in a different biopsy. (E) Levels of mRNA for TFIIIC-102 in tumour tissue
compared with normal epithelium.
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Page 10 of 16transcription factors, ATF-2 and c-Myc, are shown to be
transcriptionally upregulated, with EBNA1 being present
at the promoters both of these genes and those of
TFIIIC subunits. EBER expression is shown to be
adversely affected by reduction of ATF-2 and c-Myc,
highlighting the significance of EBNA1’s ability to
induce these transcription factors. Furthermore, EBNA1
was shown to enhance levels of EBER expression, illus-
trating its importance in the characteristic abundant
expression of EBERs that is associated with EBV latent
infection.
Our findings build upon our previous study [29]
which demonstrated that cellular pol III transcription
and TFIIIC are induced in EBV-infected epithelial cells.
The significance of increased levels of cellular pol III
transcription is not restricted to increased levels of viral
transcripts such as the EBERs. It is well-established that
pol III transcription is often deregulated in a wide range
of malignant tumours and transformed cells [38,42-44].
Furthermore, recent data suggest that increased pol III
transcription is necessary or even sufficient to promote
proliferation and oncogenic transformation in some
contexts [38,45]. Our in vivo findings support the idea
of increased pol III transcription in malignant tumours,
where induction of pol III-specific transcription factors
was observed in NPC tumour samples at both the
mRNA and protein level. Given our evidence for induc-
tion of TFIIIC subunits in EBNA1-expressing epithelial
cells, and the well-established association between EBV
and NPC, it is tempting to speculate that increased
TFIIIC subunit levels in NPC tumour cells could be
mediated, at least in part, by EBNA1.
Our data also address EBNA1’s role in upregulation of
the transcription factor ATF-2 that has previously been
shown to be important for expression of EBERs
[20,46,47]. Earlier studies are conflicting in their descrip-
tions of the effect of EBV on ATF-2. Initial studies
revealed that EBV triggers hyperphosphorylation of
ATF-2 leading to increased activity [1,48-51], with
increased levels of mono-phosphorylated ATF-2 being
observed in the absence of any increase in total levels of
ATF-2. However, recent data from our laboratory [31]
revealed that EBNA1 increases the level of ATF-2 tran-
scription and that it is present at the promoter of the
gene. Using shRNA, in the current work we show that
by reducing ATF-2 transcripts, levels of both EBERs are
reduced significantly in EBV-infected Ad/AH cells (Fig-
ure 9a). This supports the previous data suggesting the
importance of ATF-2 and ATF-2 binding sites upstream
of EBER genes to the expression of EBER transcripts.
Further, our data illustrating increased levels of both
total and phosphorylated (activated) ATF-2 suggest that
EBNA1 acts to increase EBER expression both through
induction of ATF-2 transcription and the resultant
increase in levels of dual-phosphorylated and activated
ATF-2.
Through its interaction with TFIIIB, c-Myc can
directly activate many cellular pol III-transcribed genes
[41]. This is consistent with the observed decrease in
tRNA expression that accompanies c-Myc RNAi (Figure
9b). However, EBER2 appears to be an exception, as it
shows little response to RNAi or overexpression of c-
Myc, at least in Ad/AH cells (Figure 9b-d). This may
reflect the unusual promoter arrangement and factor
requirements of EBER genes, which differ from most
cellular pol III promoters [29]. In contrast to EBER2,
the upstream regulatory region of EBER1 contains two
adjacent E-box DNA sequences that can be bound
directly by c-Myc [21]. By excising a short region con-
taining these motifs, we revealed its requirement for
induction by activated MycER (Figure 9d). This con-
trasts with a previous report that this upstream region
has little importance for EBER1 expression in 293 cells
[47]. Differences between cell types or the fact that the
earlier work [47] used a transient transfection assay may
be responsible for the discrepancy. Our data suggest
that the EBER genes show differential responsiveness to
c-Myc due to E-box DNA motifs upstream of the
EBER1 promoter. Our results showing upregulation of
c-Myc in response to EBNA1 are consistent with the
findings of an earlier study [35]. In contrast, another
study [52] found that expression of EBNA1 led to a
reduction in the level of c-Myc. The authors of this lat-
ter study [52] propose that cell- and tissue-specific
effects may be responsible for a variety of discordant
observations.
Since EBNA1 induces EBER-associated cellular tran-
scription factors, associates with their promoters (Figure
7, [31]) and has been shown to bind to multiple sites
within the human genome [53], we addressed the possi-
bility of EBNA1 association with multiple EBER-related
transcription factors using chromatin pull-down experi-
ments and found EBNA1 to be associated with the pro-
moters of these factors. The presence of EBNA1 at
these promoters affords a potential mechanistic insight
into EBNA1’s mode of action in enhancing expression
of EBERs. The nature of the interaction between
EBNA1 and upregulated genes is, at present, unknown.
However, whilst the EBNA1-binding motif defined in
t h eE B Vg e n o m ew a sa b s e n tf r o mt h ep r o m o t e r st h a t
show EBNA1 association, two recent studies have
reported that EBNA1 can bind to cellular genomic DNA
[52,53]. Further, Canaan et al. [52] identified several,
hitherto uncharacterised EBNA1 DNA binding motifs
present in the promoter regions of cellular genes. We
found that two of these, WTACTTT and GRAGTATY
were present within 1 kb of the transcriptional start
sites of the EBNA1-associated ATF2, c-Myc, TFIIIC220
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o fd e t e c t i o ni no u rC h I Pa ssays). In contrast, these
motifs are not present in the promoters of c-Jun or the
other TFIIIC subunits whose expression was found to
be up-regulated in EBNA1 expressing cells and for
which HaloChIP assays indicated EBNA1 binding at
their promoters. It is possible that EBNA1’si n t e r a c t i o n
with cellular promoters may be direct in some instances
yet indirect in others. Elucidating the mechanisms by
which EBNA1 associates with different cellular promo-
ters warrants further investigation.
Although our data indicate that EBNA1, through a
variety of mechanisms can induce EBER expression, we
note that the levels of expression in this model system
are low when compared with those in Ad/AH cells sta-
bly infected with EBV. This may be attributable to the
EBER expression plasmids in the model system being
maintained in an integrated form. In this context it is
notable that the Namalwa cell line, in which EBV is
known to be integrated at low copy number [54], also
expresses the EBERs at low levels [18,55], similar to
those seen in our model system (Figure 8b). In the con-
text of whole virus infection, the EBV genome is usually
maintained as a multi-copy episome. In this scenario,
transcription factor binding access and kinetics may be
very different, given that the EBER genes are adjacent to
oriP, within the region of unusual chromatin structure
[47]. The oriP region (absent from the Ad/AH-EBER
cell line) is also known to be a transcriptional enhancer
region [32,34] and has been previously demonstrated to
increase EBER expression by 2- to 4-fold [47]. The
number of copies of the EBER genes integrated into the
Ad/AH-EBER cell line generated is unknown, though it
is unlikely to reach the number of viral episomes carried
by EBV-infected Ad/AH cells. Further, it is of note that
EBNA1 does not seem to be capable of inducing TFIIIB
subunit expression. We anticipate that pol III-tran-
scribed genes (such as the EBERs) would be even more
highly expressed in cells in which TFIIIB was induced in
addition to TFIIIC, an environment which is observed
in EBV-infected cells [29].
Conclusions
EBNA1 has previously been shown to possess transcrip-
tional-regulatory properties for a number of pol II-
dependent EBV latent genes. The data presented here
extend the repertoire of its stimulatory mechanisms to
include the pol III-transcribed EBER genes. This could
have a major impact, given reports of EBER oncogeni-
city. Cellular pol III products are also induced by
EBNA1. Its capacity to produce these effects can be
explained by an ability to bind and activate expression
of genes encoding ATF-2, c-Myc and TFIIIC,
transcription factors shared by the viral and cellular pol
III templates.
Methods
Plasmids
The EBNA1 expression plasmid pSG5 EBNA1 [33], c-
Myc reporter pX-CMVp-Luc [21] and dominant-nega-
tive EBNA1 expression vector EBNA1-M1 [56] were as
described. A plasmid containing a functionally-induci-
ble c-Myc gene (a fusion between the hormone bind-
ing domain of the oestrogen receptor and c-Myc) [57]
w a so b t a i n e df r o mC .T s e l e p i s .A nE c o R If r a g m e n t
containing the fusion (c-MycER) was ligated into
pcDNA3.1/zeo (Invitrogen). The pUC19 EBERs plas-
mid was generated by inserting the 1 kb SacI - EcoRI
s u b f r a g m e n tf r o mt h eE c o R IJf r a g m e n to ft h eE B V
genome into the corresponding sites of pUC19, with a
puromycin resistance cassette [58] being inserted at
the SalI site. For generation of pUC19 Puro EBERs ΔX,
the X-box c-Myc binding site was excised from pUC19
EBERs plasmid using SacI and PmlI, excising bases
-352 to -125 relative to the EBER1 transcriptional start
site. A control Renilla luciferase plasmid (pRL-TK) was
from Promega.
Cell lines and tissue culture
Ad/AH (a human adenocarcinoma cell line derived from
the nasopharynx), HONE-1 (an EBV-negative NPC cell
line) and AGS (human gastric carcinoma-derived) cell
lines were cultured in RPMI 1640 medium supplemen-
ted with 10% fetal calf serum (FCS), 2 mM L-glutamine
and 1% penicillin-streptomycin solution (Sigma-Aldrich).
HONE-1 and AGS cells stably expressing EBNA1 and
the Ad/AH line stably infected with a recombinant EBV
were described previously [35]. An Ad/AH cell line that
stably expresses physiological levels of EBNA1 (Figure 2)
was derived as described previously [35].
Ad/AH-Neo and -EBNA1 cells stably expressing the c-
MycER fusion protein were generated by transfection of
cells with c-MycER plasmid followed by drug selection
with Zeocin (Invitrogen). Ad/AH-EBERs cell lines (and
derivatives) were generated by stable transfection of
pUC19 EBERs plasmid, followed by puromycin drug
selection of polyclonal EBER-positive cell populations.
Luciferase assays and transient transfections
Dual luciferase reporter assays were performed accord-
ing to the manufacturer’si n s t r u c t i o n s( P r o m e g a )w i t h
cells cultured in RPMI 1640 supplemented with 0.5%
FCS, 2 mM L-glutamine, and 1% penicillin-streptomycin
solution. Cells were transfected with plasmids using
Lipofectamine (Invitrogen) according to the manufac-
turer’s instructions. All assays were carried out in
Owen et al. Molecular Cancer 2010, 9:241
http://www.molecular-cancer.com/content/9/1/241
Page 12 of 16biological and technical triplicate and are represented as
the mean of three independent experiments.
Cells were subjected to shRNA directed against c-Myc
(pGIPZ 152051, OpenBiosystems) and ATF-2 (pLKO.1
13713, OpenBiosystems) using transfection techniques
previously outlined. RNA was extracted from cells 72 h
post-transfection.
ChIP assays
ChIP assays were performed as described previously [31]
using an EBNA1 antibody (chEBNA1) and conditions
described by Chau & Lieberman (2004) [39]. A rabbit
isotype control antibody was obtained from Santa Cruz.
Precipitated target sequences were identified by PCR
and quantitated by densitometry as described below.
HaloCHIP assays
HaloCHIP assays were performed according to the man-
ufacturer’s instructions (Promega, UK). HaloEBNA1
fusion protein-encoding plasmid was generated using
PCR based cloning techniques, with pseudo-wild type
EBNA1 (with deleted Gly/Ala repeat region) fused to
HaloTag protein (N-terminal) in pFC14K-CMV back-
bone plasmid (Promega UK). 0.5 μg HaloEBNA1 plas-
mid was transfected per 10 cm
2 dish. Dishes were
formaldehyde cross-linked 24 h post transfection before
manufacturer’s protocols were followed precisely.
PCR was performed using GoTaq Green Polymerase
Mastermix (Promega UK). Primer sets for promoter
regions were designed with the aid of literature searches
for known promoter regions. All primer sets were based
upon regions within 1 Kb upstream of transcriptional
start sites. Exceptionally, primer sets for cellular pol III-
transcribed genes tRNA
Tyr and 5S RNA were based, due
to their intragenic promoters, on regions internal to the
gene. 7SL RNA’s promoter regions are both intragenic
and upstream of the transcriptional start site therefore
primer sets for both regions were used. Primer sets are
listed in Table 1. The linear range of each PCR reaction
was determined empirically through semi-quantitative
PCR to determine experimental cycle numbers.
RT-PCR, immunoblotting, immunofluorescence and
immunohistochemistry
RNA for RT-PCR was reverse transcribed with Super-
script III, (Invitrogen) following the manufacturer’s pro-
tocol, using random primers (Promega UK). Resultant
cDNA was then used for PCR reactions as above. Pri-
mers are listed in Table 2. Standard immunoblotting
procedures [35] were used to detect total ATF-2,
(mouse MAB1536, 1 mg/ml, Santa Cruz), mono-
(Thr69) and dual-phosphorylated (Thr69/71) ATF-2
(mouse MAB1536 1 mg/ml, Cell Signaling Technology),
EBNA1 (human serum, 1:500), actin (mouse AC-38,
1:20 000, Sigma). Immunoblotting for TFIIIC subunits
was performed as described previously [29]. Immunohis-
tochemical staining and EBER in situ hybridisation were
performed on biopsies used in previous studies [59] and
were conducted as described therein. For immunohisto-
chemistry, antibody 3238 to TFIIIC-102 [29] was used
at a dilution of 1:100 following standard techniques.
Immunofluorescence was carried out on Ad/AH-Neo
and -EBNA1 cells using standard procedures [35] with
total ATF-2 antibody (mouse MAB1536, 0.5 mg/ml,
Santa Cruz).
Table 1 PCR primers used in ChIP and HaloCHIP
experiments
Gene (promoter
region)
Primer oligonucleotides (5’-3’)
TFIIIC220* Forward: GTTTGCAGTTCCCCTGGTTAC
Reverse: CTTCGTCCAACAACGACTCC
TFIIIC110* Forward: TCTCCCCTTTTTGACACTGC
Reverse: AGGGGGAGGAGTAATTGTGG
TFIIIC102 Forward: CGGTTCCTTGCTCTTGCT
Reverse: GCATCGCCTCACTTTCTT
TFIIIC90 Forward: GCGGGTAGGGACAAGACT
Reverse: CCCAGACAGGCTTTAGTT
TFIIIC63 Forward: GCCAACACCGACAGAATA
Reverse: CGGAGGATAATAAGACACAAA
5S RNA Forward: TTTACGGCCACACCACCCTG
Reverse: AAAGCCTTCAGCACCCTGTA
tRNA
tyr Forward:
CCTTCGATAGCTCAGCTGGTAGAGCGGAGG
Reverse:
CGGAATTGAACCAGCGACCTAAGGATGTCC
7SL RNA
(gene)
Forward:
GTGTCCGCACTAAGTTCGGCATCAATATGG
Reverse:
TATTCACAGGCGCGATCCCACTACTGATC
7SL RNA
†
(upstream promoter)
Forward: CCGTGGCCTCCTCTACTTG
Reverse: TTTACCTCGTTGCACTGCTG
Brf1 Forward: GCAAGGAGGTCAGGCACT
Reverse: CCTTCCACGGCTACCTCT
Bdp1 Forward: GTTTCTTCACACCAGCATT
Reverse: GCTACTGAGACTGGGTTA
TBP Forward: CGCCCCTCCTTACCTAT
Reverse: CAATCTGTTACCTGGGTC
ATF-2 Forward: CCCAAACCTCACCTAACCCGAAG
Reverse: CTCGGGCGCTCATGATTGGACAA
c-myc Forward: TCCTCTCTCGCTAATCTCCGC
Reverse: CCCTCCGTTCTTTTTCCCG
c-jun Forward: CCCACAAGTGGGGAAACAACAA
Reverse: GCTACCAGTCAACCCCTAAAAATA
GAPDH Forward: TACTAGCGGTTTTACGGGCG
Reverse: TCGAACAGGAGGAGCAGAGAGCGA
EBV-DS Forward: CCGTGACAGCTCATGGGGTGGGAGAT
Reverse: CAATCAGAGGGGCCTGTGTAGCTACCG
EBERs Forward: CCGCCTACACACCAACTAT
Reverse: GGGATTAGAGAATCCTGACTT
* Primer sets previously described [29].
†Primer set previously described [62].
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Densitometry was conducted on UV transilluminator
images using ImageJ 1.37 V (http://rsbweb.nih.gov/ij/).
Bands were analysed in technical triplicate, normalising
against background image levels and, if appropriate,
internal controls. In all instances, densitometry was con-
ducted in biological triplicate.
Quantitative RT-PCR (RT-qPCR)
RT-qPCR for cellular genes was performed using ready
synthesised Taqman primer and probe (FAM labelled)
mixes purchased from Applied Biosystems (see Table 3).
Each multiplexed RT-qPCR reaction consisted of 5 μl
(50 ng) of cDNA, 1 μl of ABI test primers and probe
mix, 0.5 μl of huGAPDH primer and probe (VIC
labelled) mix, 10 μl of 2× sensimix (Quantace) and
DEPC water to 20 μl. Reactions were performed in bio-
logical and technical triplicate and analysed on an ABI
7500 Fast Real-time PCR machine. Data were analysed
using the 2
-ddCt method [60].
Microarray analysis of nasopharyngeal carcinoma (NPC)
tumours
Full details of the protocol will be presented elsewhere
(C. Hu et al., in preparation). Briefly, normal epithelial
cells and EBV-positive NPC tumour cells were isolated
by laser-capture microdissection from frozen biopsies.
Total cellular RNA was extracted using a Qiagen
RNEasy kit followed by amplification, labelling and
hybridisation to Affymetrix U133 Plus2 arrays essen-
tially as previously described [61]. After scanning,
intensity values were analysed using GCOS software
(Affymetrix).
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Table 2 RT-PCR primers
Gene Primer oligonucleotides (5′-3′)
ATF-2 Forward: CACACAACTCCACAGACCCAAA
Reverse: GGAGCCATAACGATCTGTGAAA
c-Myc Forward: AACCAGAGTTTCATCTGCGACCCG
Reverse: TTGTGCTGATGTGTGGAGACGTGG
5S RNA* Forward: TTTACGGCCACACCACCCTG
Reverse: AAAGCCTTCAGCACCCTGTA
tRNA
tyr* Forward: CCTTCGATAGCTCAGCTGGTAGAGCGGAGG
Reverse: CGGAATTGAACCAGCGACCTAAGGATGTCC
7SL RNA * Forward: GTGTCCGCACTAAGTTCGGCATCAATATGG
Reverse: TATTCACAGGCGCGATCCCACTACTGATC
TFIIIC 220* Forward: TCCAGCGAGACCGTCACACC
Reverse: GGATTGAGTGTTGCTGGGCT
TFIIIC 110* Forward: CCAGAAGGGGTCTCAAAGTCC
Reverse: CTTTCTTCAGAGATGTCAAAGG
TFIIIC 102* Forward: GCAGAAGTAACATCATTGGC
Reverse: CCTACTAATGTCCGTTATCTGTGG
TFIIIC 90* Forward: AAACAGAAGTTGCTGAGTGC
Reverse: ATGGTCAGGCGATTGTCC
TFIIIC 63* Forward: ATGGCTTGAAGTCCTCCTCCTCC
Reverse: CCGAGATGTTCTACCAGTTATGCG
Bdp1* Forward: GCTGATAGAGATACTCCTC
Reverse: CCAGAGACAAGAATCTTCTC
Brf1* Forward: AAATTCTGTGAGCCTCTTCCGTAGTG
Reverse: AGACCCATGCTTGTACATTCCACG
TBP* Forward: GCCAGAGTTATTTCCTGGTTT
Reverse: CCCAGATAGCAGCACGGTAT
GAPDH Forward: GCCTCCTGCACCACCAACTG
Reverse: CGACGCCTGCTTCACCACCTTCT
EBER1 Forward: AGGACCTACGCTGCCCTAGA
Reverse: AAAACATGCGGACCACCAGC
EBER2 Forward: GCCGTTGCCCTAGTGGTTT
Reverse: GGGATTAGAGAATCCTGACTT
EBNA1 Forward: CCGCAGATGACCCAGGAGAA
Reverse: TGGAAACCAGGGAGGCAAAT
* Primer sets previously described [29].
Table 3 Applied Biosystems q-PCR assays
Gene ABI QPCR Primer/Probe Reference Number
TFIIIC220 Hs01121460_m1
TFIIIC110 Hs01086775_m1
TFIIIC102 Hs01066489_m1
TFIIIC90 Hs01034271_m1
TFIIIC63 Hs01030747_m1
BDP1 Hs00372575_m1
BRF1 Hs00377388_m1
TBP Hs00920494_m1
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